35748-34-6Relevant articles and documents
Substituted pyrazole compound, preparation method, pharmaceutical composition and applications thereof
-
Paragraph 0213-0217, (2020/03/12)
The invention discloses a substituted pyrazole compound represented by a formula I, and a preparation method, a pharmaceutical composition and applications thereof, wherein the compound has characteristics of good stability, excellent solubility, low cytotoxicity and remarkable neuroprotective effect, can effectively prevent and treat nerve cell injury, and is an ideal medicinal compound for preventing or treating cerebral stroke, cerebral embolism, cerebral stroke sequelae, cerebral stroke dyskinesia, mitochondrial encephalomyopathy and amyotrophic lateral sclerosis of spinal cord.
Benzo wicked zuozuo apperception compound and its preparation and use
-
Paragraph 0046-0048, (2017/10/27)
The invention provides a benzoxazole compound. The structure of the benzoxazole compound is shown in the formula (I), wherein R1, R2, R3 and R4 are hydrogen, C1-C5 alkyl, benzyl, aryl or hetero aryl. The preparation method of the benzoxazole compound is carried out according to the following reaction route. Compared with the prior art, the benzoxazole compound has the benefits that the Sortase A protease of bacteroid is used as a target spot, a similar structure of a Sortase A substrate is constructed through the action mechanism of the known Sortase A and the cell wall of a host cell, and new compounds with benzoxazole and mother nucleus are synthesized; the new compounds carry out the test screening of Sortase A activity inhibition so as to try to find candidate compounds for effectively inhibiting staphylococcus aureus infection.
COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF
-
Paragraph 0138, (2016/10/27)
PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT